Development of a Novel Enzyme-Linked Immunosorbent Assay and Lateral Flow Test System for Improved Serodiagnosis of Visceral Leishmaniasis in Different Areas of Endemicity
Visceral leishmaniasis (VL) is caused by protozoan parasites of the Leishmania donovani complex and is one of the most prominent vector-borne infectious diseases with epidemic and mortality potential if not correctly diagnosed and treated. East African countries suffer from a very high incidence...
Saved in:
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Philipps-Universität Marburg
2023
|
Subjects: | |
Online Access: | PDF Full Text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Visceral leishmaniasis (VL) is caused by protozoan parasites of the Leishmania
donovani complex and is one of the most prominent vector-borne infectious diseases with
epidemic and mortality potential if not correctly diagnosed and treated. East African countries
suffer from a very high incidence of VL, and although several diagnostic tests are
available for VL, diagnosis continues to represent a big challenge in these countries due
to the lack of sensitivity and specificity of current serological tools. Based on bioinformatic
analysis, a new recombinant kinesin antigen from Leishmania infantum (rKLi8.3) was developed.
The diagnostic performance of rKLi8.3 was evaluated by enzyme-linked immunosorbent
assay (ELISA) and lateral flow test (LFT) on a panel of sera from Sudanese, Indian,
and South American patients diagnosed with VL or other diseases, including tuberculosis,
malaria, and trypanosomiasis. The diagnostic accuracy of rKLi8.3 was compared with rK39
and rKLO8 antigens. The VL-specific sensitivity of rK39, rKLO8, and rKLi8.3 ranged from
91.2% over 92.4% to 97.1% and specificity ranged from 93.6% over 97.6% to 99.2%,
respectively. In India, all tests showed a comparable specificity of 90.9%, while the sensitivity
ranged from 94.7% to 100% (rKLi8.3). In contrast to commercial serodiagnostic tests,
rKLi8.3-based ELISA and LFT showed improved sensitivity and no cross-reactivity with other
parasitic diseases. Thus, rKLi8.3-based ELISA and LFT offer improved VL serodiagnostic efficiency
in East Africa and other areas of endemicity. |
---|---|
Item Description: | Gefördert durch den Open-Access-Publikationsfonds der UB Marburg. |
DOI: | 10.1128/spectrum.04338-22 |